AntePC genetic test provides men with personalized risk assessment for prostate cancer using a polygenic risk score (PRS).
Prostate cancer is the most common cancer in men, which goes asymptomatic in its early stages. AntePC provides advanced solution for the timely detection of increased cancer risk. Our risk calculations take into account the current incidence rate of the target population and available genetic data. AntePC clinical recommendations are based on the individual results of the test and recommendations from the international medical organizations (e.g. The European Urological Association Guidelines). The purpose of the AntePC test is to reduce the risk of premature mortality due to prostate cancer by more accurate screening.
AntePC is a registered in vitro diagnostic device (IVD medical device) and it has been developed by the healthcare service provider Antegenes (License: L04685).
What does AntePC test include?
- Analyzes of 121 genetic variants associated with prostate cancer;
- Individual polygenic risk score for prostate cancer;
- The individual risk of prostate cancer compared to the rest of the male population;
- Likelihood to get prostate cancer in 10 years and risk assessment compared to a man with average genetic risk;
- Interpretation of the test results with clinical recommendations;
- Genetic counseling.
Who can benefit from AntePC?
AntePC test is recommended for:
- Males between the ages of 40-70 of European origin (Note: Genetic risk studies used by AntePC have been conducted in populations of European descent).
The AntePC test is not recommended:
- If the patient has a high-risk mutation in single genes predisposed to prostate cancer (BRCA1, BRCA2, ATM, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, etc.).
What is needed for AntePC testing?
AntePC testing requires the patient’s DNA, which is collected and isolated from the buccal swab sample (cells inside the cheek are collected with a special cotton swab).
How long does it take to get AntePC test results?
Test results are available within 6 weeks from the sample being received by Antegenes.
AntePC Test Limitations
- AntePC test is not used to diagnose prostate cancer.
- AntePC test is not validated for use by individuals of non-European descent.
- An elevated risk estimated by the AntePC test does not mean that the patient will develop prostate cancer during their lifetime. Also, a moderate or lower risk does not mean that the patient will not develop the disease.
- AntePC test is patient-specific and does not assess the risk of the patient’s family and relatives, i.e. polygenic risk score-based disease risks may not be transmitted directly from parents to children
- AntePC test does not analyze rare pathogenic mutations in genes that significantly increase the risk of prostate cancer, such as BRCA1, BRCA2, ATM, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6 and others.
- The AntePC test is based on the most up-to-date scientific data, which may, however, be supplemented and changed in the future as additional information becomes available. The field of genetics is constantly evolving, which may lead to changes in risk assessments over time, as well as changes in test selection recommendations and clinical recommendations based on test results.
- Different polygenic risk scores predicting risks of the same trait may give different estimates of the individual’s risks due to differences in the genetic variants included in the models and their weights.
- The results of this test should be applied in context with other relevant clinical data. In addition to the possible genetic predisposition, other risk factors also influence the risk of prostate cancer.